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Background: Globally, attendance at cardiac rehabilitation (CR) is between 15 and 30%. 
Alternative models of individualised care are recommended to promote participation in CR, 
however there has been no prospective testing of different durations of such models. We 
aimed to replicate the previously proven Choice of Health Options In prevention of 
Cardiovascular Events (CHOICE) intervention, and to determine if an extended version 
(CHOICEplus) would confer additional benefits. 
Methods: Acute coronary syndrome (ACS) survivors not accessing centre-based CR 




(n = 103) at four urban hospitals. The program comprised telephone-based tailored risk-
factor reduction. 
Results: CHOICE and CHOICEplus were equivalent demographically and in risk profile at 
baseline. At 24 months, lipid profiles improved significantly and fewer patients had ≥3 risk 
factors above target compared to baseline in both groups. There were no significant 
differences between groups. 
Conclusions: The 24-month CHOICEplus program did not confer additional benefit above 
the brief 3-month CHOICE intervention. However, participation in either CHOICE and 
CHOICEplus significantly improved cardiovascular risk profile in ACS survivors.  Importantly, 
the study was feasible, and the intervention translated readily across four hospitals. Overall, 
this study adds to the existing evidence for brief individualised approaches to CR. 
Keywords: Secondary prevention, Telehealth, Cardiac rehabilitation 
 
INTRODUCTION 
Attendance at a formal secondary prevention program, usually termed cardiac rehabilitation 
(CR), includes evidence-based strategies that have been demonstrated to lower 
cardiovascular risk factors, improve quality of life and decrease morbidity and mortality and 
is recommended in national and international guidelines for all patients after a cardiac 
event.1 However, formal prevention programs are typically time-limited, facility-based and 
conducted in groups, in a model largely unchanged for decades.2 Globally, attendance at CR 
is consistently low.3, 4 Most recently, an Australia-wide audit identified that only 46% of 
patients presenting to hospital with an acute coronary syndrome (ACS) are referred to CR, 
with only 27% receiving optimal preventive care.5 Concern over poor referral and attendance 
at facility-based CR has led to the evolution of new models to increase access to effective 
secondary prevention.6 
Alternative models of individualised care include telephone-based models such as Coaching 
patient On Achieving Cardiovascular Health (COACH)7 and Choice of Health Options In 




and intensity of delivery of these individualised programs.9 CHOICE was a brief 3-month 
intervention, which focussed on establishing an ongoing therapeutic alliance between patients 
and health professionals, where patients are active partners in managing their disease.8 Testing 
of the CHOICE intervention showed sustained benefit at 1 year8 and 4 years.10 Although a 
systematic review concluded brief programs of up to 10 hours are as effective as longer 
programs,9 to date, there has been no prospective testing of different durations of alternative 
secondary prevention program, or whether they can be sustained in the longer term. 
Randomised controlled trials (RCT) focus on a set of tightly controlled circumstances, which 
may not be closely related to clinical practice.11 Thus, replication studies can bridge the gap 
between RCTs and real world practice, and provide important information on population-
level scalability.12 We aimed to determine if an extended 24-month intervention has 
additional benefit on cardiovascular risk factors compared to the previously proven 3-month 
CHOICE intervention in ACS patients; to determine if participation in either CHOICE 
intervention improves cardiovascular risk factor profile from baseline to 24-months; to 
investigate the feasibility and generalisability of the CHOICE intervention, and to investigate 
the benefit of an additional nutrition module, a tailored approach to management of 
depression, and to validate self-reported physical activity. 
MATERIAL AND METHODS 
Study Design 
This replication study with 24-month follow-up was conducted at four tertiary referral 
hospitals in Sydney, Australia and is registered on the Australian and New Zealand Clinical 
Trials Registry (ACTRN12608000182392). The study was approved by the Sydney South 
West Area Health Service Human Research Ethics Committee – Concord Repatriation 
General Hospital zone (CH62/6/2007-142). At three of the four sites, ACS patients who had 
declined an offer from the CR team to participate in standard CR, or did not attend the initial 




tested 3-month CHOICE program or a 24-month CHOICE program (CHOICEplus) (Figure 
1). At the remaining site, ACS patients not accessing CR were randomised to one of three 
groups: CHOICE, CHOICEplus, or a comparator group participating in conventional care, 
which allowed investigation of the effect of the addition of nutrition module and depression 
management.  
The study protocol has been described in detail previously.13 Briefly, to identify eligible 
participants, CR coordinators reviewed the cardiology department admission summaries 
daily. Participants were eligible if they had an ACS diagnosis up to 8 weeks prior to 
recruitment, and excluded if they had a clinical diagnosis of a severe coexisting medical 
condition that would prevent participation, or insufficient English to provide written informed 
consent. The intervention for both groups comprised a tailored risk factor reduction with an 
initial clinic visit and follow-up phone support (Figure 2). Individuals could choose up to three 
tailored modules to address risk factors. The modules were cholesterol management, blood 
pressure management, physical activity, diet, and smoking cessation. Within each module, 
participants could choose how they wanted to manage the risk factor from four options: 
medical; hospital-based; home-based; or self-directed.  For CHOICE, this was delivered over 
3 months; for CHOICEplus, the intervention was intended to be delivered over 36 months, 
but was shortened to 24 months due to local site resourcing issues. The intended number of 
telephone calls was four for CHOICE participants and eight for CHOICEplus participants. 
Frequency of calls was determined by a mutual agreement. The intervention was 
underpinned by social cognitive theory14 and encouraged formation of a therapeutic alliance 
between participants and health care providers.15 Compared to the previously tested 
CHOICE study,8 a single-centre study with a single clinician (physiotherapist) delivering the 
intervention, this study was conducted at four hospitals in culturally diverse areas of Sydney, 





The primary outcome measures were total cholesterol (TC), measured by fasting blood sample; 
systolic blood pressure (SBP) using standardised procedures;16 smoking status (self-report and 
carbon monoxide measure);17 and physical activity (Active Australia Survey (AAS), validated 
with accelerometer).18 Secondary outcomes included readmission rates, all-cause mortality, 
cardiac mortality, proportion with three or more cardiac risk factors (smoking, SBP >140 mmHg, 
LDL >2.5 mmol/l, BMI ≥30 kg/m2, physical inactivity) above the targets set by the National Heart 
Foundation of Australia,19 waist circumference, quality of life and dietary intake, determined by a 
nutritional screening tool.20 For quality of life, the physical component score (PCS) and mental 
component score (MCS) were derived from the SF-12 instrument. The sub-components 
were scored based on normative data from the US general population21 which has been 
demonstrated appropriate for use in studies of the Australian population.22   
To evaluate the generalisability of the previously supported CHOICE study,8 process evaluation 
measures of the intervention included: record of participant recruitment, withdrawal from the 
program, the context of the interventions and the resources used and assessment of barriers to 
implementation and fidelity to the intervention components. 
Validation of the Active Australia Survey 
Self-reported physical activity using the AAS23 was validated in a subset of participants (n=54) 
at 12 months. Each participant wore an ActigraphGT1M accelerometer for 7 days then 
completed the AAS.  
Valid data were obtained for 4 or more days from 46/54 participants. We analysed the data 
with the complete set of questions and also with question 4 removed. Question 4 asks 
participants to estimate the total time spent doing “vigorous gardening or heavy work around 
the yard” over the past week. Previous studies have shown that question 4 does increase 
over-reporting of moderate to vigorous physical activity.24 There was modest correlation for 
the complete AAS and the accelerometry data (0.266) (mean AAS 491 (SD 239); mean 




(0.526) (mean AAS 344 (SD 246); mean accelerometry 239 (SD 165)). Therefore, final 
results were analysed with question 4 removed. Further, accelerometry data showed 
moderate to vigorous physical activity was slightly correlated with AAS reported moderate to 
vigorous physical activity (R2=0.168).  This corresponds well with the literature for self-
reported physical activity data,24 and was considered acceptable for reporting of physical 
activity data for participants this study.  
Validation of the dietary assessment 
Validation of our dietary assessment was conducted by comparing the nutritional screening 
tool used here against a multiple pass dietary assessment (conducted by a qualified 
dietitian) which has been published previously.20 These results show high correlation for 
alcohol, fish, and fruit and vegetables with a multiple pass dietary assessment. There is 
lower correlation for soluble fibre and monounsaturated fats, perhaps due to these items 
being harder to quantify in the diet. Therefore, only intake results of alcohol, fish and fruit 
and vegetables are presented here.  
Statistical Analysis 
Our sample size was based on the previous CHOICE study and was calculated on reduction 
in TC of 0.35 mmol/l from baseline to study end. Our aim was to recruit 276 participants (138 
per group) with an alpha error rate of 0.05 and power of 0.8. We imputed missing data by 
imputing the mean value of the variable (estimated by the Expectation-Maximisation 
algorithm in the MI procedure) at each time point for each arm. For binary variables this was 
rounded to between 0 and 1 (i.e. no negative numbers or numbers greater than 1), the 
outcome set to ‘1’ and the imputed value used as a weight in the analysis. Non-missing 
values were given a weight of 1. Summary data were produced for each group (CHOICE, 
CHOICEplus) at each time-point (baseline, 24 months). First, we tested whether there was 
difference in outcome variables between CHOICE and CHOICEplus groups at 2 years using 




and Pearson’s chi-squared test for binary outcomes. Secondly, we compared changes over 
time when these two groups were combined using paired t-tests for continuous outcomes 
and McNemar’s test for binary outcomes. As a sensitivity analysis to check that the results of 
an analysis of change are comparable to a single final measurement, we have used 
generalised estimating equation (with exchangeable correlation structure) to avoid the 
assumption of sphericity in RM-ANOVA and to allow the analysis of outcomes other than 
continuous measurements. We estimated the differential effects of group on time, and 
included adjustments for age, sex, country of birth, working status and tertiary education. All 
tests were undertaken in SAS 9.4 (Sydney, NSW, Australia). 
RESULTS 
Participants 
We identified 1764 patients across the four hospital sites who were admitted with an ACS, of 
whom 888 were eligible for secondary prevention (Figure 1). Following blinded baseline 
assessment, 203 patients who were not accessing CR were randomly allocated to CHOICE 
(n=100) or CHOICEplus (n=103). Data were complete at 2 years for 168 participants: 79 in 
CHOICE; and 89 in CHOICEplus. A further 67 participants were randomly allocated to a 
comparator group at one site to validate the nutrition module and the tailored approach to 
depression. Data were complete at 2 years for 61 in the comparator group. There was no 
difference in drop-out rate between the groups. 
Baseline characteristics are shown in Table 1. There were no significant differences between 
the groups at baseline. Most participants were aged in their early 60s, and the majority were 
male. Around half were currently working and just over a third had a previous history of CVD. 
The majority were admitted with unstable angina and around two-thirds had a 
revascularisation procedure during their ACS presentation. The mean baseline TC was 4.2 





No significant differences were found between CHOICE and CHOICEplus in any variable at 
24 months (Table 2). In a sensitivity analysis using multiple imputation for patients with a 
missing final outcome, there was no evidence of an important difference between groups 
(p=0.147). When we combined the groups, and analysed differences from baseline, total 
cholesterol improved significantly, while blood pressure increased significantly (Table 3). In 
the combined groups, the percentage smoking reduced, however this did not achieve 
significance. There was a significant decrease in the proportion of participants with three or 
more risk factors above the national targets. The further sensitivity analysis showed the only 
outcome for which we had a different effect from just one measurement was for HDL level, 
where, with the extra adjustments, we found a change over time but no difference in change 
over time between groups. 
Secondary Outcomes 
There were two deaths in the CHOICE group, both due to non-cardiac causes, and no 
deaths in the other groups. In the CHOICE group there was one readmission for a 
cardiovascular cause unrelated to coronary artery disease (aortic valvuloplasty) and one for 
non-cardiovascular cause (shoulder surgery). In the CHOICEplus group there were two 
readmissions for cardiovascular causes (septum resection for hypertrophic cardiomyopathy; 
coronary angiogram) and one for a non-cardiovascular cause (bladder cancer). In the 
comparator group there was one readmission for a cardiovascular cause (cardioversion for 
atrial fibrillation) and one for a non-cardiovascular cause (shoulder surgery). 
Process Implementation Evaluation 
Recruitment to the CHOICE intervention was slower than anticipated. Five hundred people 
declined enrolment in the study: the principal reason was unwillingness to participate in a 
research study (n=223) (Figure 1). Follow-up was completed at 24 months, rather than the 






Telephone calls were delivered as per protocol: The CHOICE group received a mean of 4±2 
successful calls; five participants in CHOICE were not able to be contacted subsequent to 
enrolment in the trial. The CHOICEplus group received a mean of 8±3 successful calls; two 
participants in CHOICEplus were not able to be contacted subsequent to enrolment in the 
trial. The mean duration of telephone calls was 9±5 minutes (range 1–40 minutes). For each 
successful telephone call, a mean of 2±1 attempted calls (range 1–17) per participant, i.e., 
approximately 50% of calls were successful. 
Selection of modules 
In terms of module selection, 8/203 (4%) participants chose only one module; 80/203 (39%) 
chose two modules; 109/203 (54%) chose three modules; and 6/203 (3%) chose four 
modules. All participants in the interventions were required to undertake the cholesterol 
module (203/203), with the majority selecting the medical option. The majority of participants 
chose either the nutrition module (130/203, 64%), and/or the physical activity module 
(142/203, 70%), with the home based intervention as the preferred mode of delivery for both. 
Of the participants who were not sufficiently active at baseline as classified by the AAS 
(61/203), over half (38/61, 63%) elected to take up the physical activity module. Of those 
with hypertension, 26/50 (52%) chose the BP module, with just over half selecting the 
medical option. Of the 39 participants who reported smoking at the baseline assessment, 
21/39 (54%) chose the smoking module, with the majority choosing the self-directed option. 
There were no between-group differences in module selection. 
The nutrition module enabled people in the intervention groups to make significant changes 
in their diet, which were not observed in the comparator group, as reported previously.20 
However, our tailored approach to depression did not significantly reduce the mean 
depression score of people in the intervention groups (Table 2) when compared to baseline, 




Therefore, it is suggested that the nutrition module had additional benefit over the original 
four modules in the original CHOICE study, but the tailored approach to depression did not. 
DISCUSSION 
This study was a replication of the methods of a previously proven RCT of a brief 3-month 
intervention, compared to an extended 24-month intervention for ACS survivors not 
attending CR, but with assessment at 24 months for both groups. Our findings suggest that 
there was no additional benefit for the extended intervention in this sample. Participation in 
either CHOICE intervention improves cardiovascular risk factor profile from baseline to 24 
months, however, changes in cardiovascular risk factors were less pronounced than in the 
original CHOICE study.8 Of note, baseline cardiovascular risk factors and medication 
prescription were much better than anticipated from the results of the original CHOICE study 
suggesting more intensive therapy and better adherence to guidelines.8 In particular, 
baseline total cholesterol was 4.7 mmol/l in the original CHOICE study but only 4.2 mmol/l in 
the current study, while the target for cholesterol reduction remained at 4.0 mmol/l. These 
improvements in lipid levels and prescription of lipid lowering therapy for secondary 
prevention have been noted in Australia during the time period covering the two CHOICE 
studies.25 It is likely that TC goals need to be individualised and made even lower after ACS, 
when the global risk is not high and especially when the TC is close to or below the current 
target. Policy and/or guidelines should consider decline in baseline TC.  
Participants in the CHOICE intervention groups increased their physical activity levels, but 
this was not significant. It is possible that introduction of a nutrition module, not present in 
the original CHOICE intervention, lessened the impact of the physical activity module. It was 
also noted that at 1 year, participants who used the accelerometer over-reported the amount 
of physical activity that was of moderate to vigorous level by around 30%. Indeed, the 




be due to perceived social desirability of appearing physically active on the part of the 
participants.27  
For sedentary behaviour, we observed a significant increase from baseline in the number of 
hours participants reported sitting per week. Inactivity physiology suggests that, separate to 
lack of physical activity, sitting may have independent detrimental effects on cardio-
metabolic health.28 Encouraging people to adopt less sedentary patterns of behaviour is not 
traditionally included in CR programs. Given the high level of sedentary behaviour among 
the CHOICE participants, and the observed increase over 1 year, this requires further 
research to determine the impact of including interventions to reduce sedentary behaviour in 
CR. 
Importantly, the brief CHOICE intervention was easily adapted to multiple hospital sites. The 
study engaged 203 additional people who had previously declined to take part in a facility-
based CR program, and this number would likely have been higher had it not been offered 
only as part of a research study. It is likely that the CHOICE intervention (brief and extended) 
was successful because it engaged local service providers, was tailored to the individual 
needs of the patient and was delivered in a timely fashion soon after the acute event. 
Furthermore, CHOICE was based on behaviour change theories that have shown that 
patient engagement is central to making successful behaviour changes, particularly where 
long-term change is necessary to deliver lasting health benefits.29 It is therefore 
recommended that behaviour change theories should be embedded in clinical practice and 
specific consideration is given to the training needs of staff. 
An interesting finding of this study was the large number of people who refused to take part 
“because it was a research project”. It has been shown that people who refuse to participate 
in research are usually older, of lower socioeconomic status, have more cardiovascular risk 
factors and higher subsequent mortality.30 However, in this study, the participants had 




attend CR are at higher baseline risk than those who do not attend.31 It is possible that those 
at the very highest risk did not attend and this needs to be addressed in future studies, with 
some examination of the role of the consent process in the inability to enrol these high risk 
participants.  
This study has several limitations. We recruited fewer participants than anticipated, and the 
study only went for 24 months rather than planned 36 months. Although it is possible that 
this resulted in no observed differences between groups, we believe this is unlikely. 
However, we undertook sensitivity analyses to ensure that the results were not an effect of 
insufficient data points on study participants. We also found that improved background 
treatments meant that people were at significantly lower baseline risk than in previous 
studies. This particularly affected blood cholesterol, one of the primary endpoints, which was 
0.5 mmol lower than the baseline value in our previous study, so absolute changes at 24 
months were smaller. The difference in the number of telephone calls was only four over a 
24-month basis, however this was determined by mutually agreed need on a case-by-case 
basis.  In common with most trials of a lifestyle intervention, the majority of the participants 
were male, aged in the early 60s, and a number of people refused to participate because the 
intervention was research. 
CONCLUSIONS 
The 24-month CHOICEplus program did not confer additional benefit above the brief 3-
month CHOICE intervention. However, participation in either CHOICE and CHOICEplus 
significantly improved cardiovascular risk profile in ACS survivors.  Importantly, the study 
was feasible, and the intervention translated readily across four hospitals particularly where 
resourcing was sustained. The greatest value was seen in the initial 3-month period of the 
original intervention, suggesting that program structure and efficiency are important in 
designing interventions of this nature. Overall, this study adds to the existing evidence for 
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Table 1 - Baseline characteristics of participants 
 
Table 1- Baseline characteristics of participants 
 n(%) unless otherwise specified CHOICE CHOICEplus 
Number of men 82 (82) 79 (77) 
Age in years, mean (SD) 60.8 (13.3) 61.0 (10.5) 
Country of birth  Australia 55 (55) 49 (48) 
 Europe 19 (19) 28 (27) 
 Other country 26 (26) 26 (25) 
Currently working 58 (58) 48 (47) 
Tertiary qualification 30 (30) 28 (27) 
Time from ACS to baseline assessment, days, mean (SD) 52.6 (33.4) 56.5 (33.4) 
Index ACS  ST elevation MI 15 (15) 14 (14) 
 Non- ST elevation MI 60 (60) 66 (64) 
 Unstable angina 25 (25) 23 (22) 
History of cardiovascular disease 30 (30) 34 (33) 
In-patient revascularisation  Per-cutaneous intervention 62 (62) 58 (56) 
 Coronary artery bypass graft 6 (6) 10 (10) 
Total cholesterol (mmol/l), mean (SD) 4.2 (1.1) 4.2 (1.0) 
>4.0 mmol/l 54 (54) 50 (49) 
Low density lipoprotein (mmol/l), mean (SD) 2.3 (0.8) 2.3 (0.8) 
>2.5 mmol/l 30 (30) 30 (29) 
High density lipoprotein (mmol/l), mean (SD) 1.2 (0.3) 1.1 (0.4) 
Trigylcerides (mmol/l), mean (SD) 1.7 (0.9) 1.8 (1.3) 
Blood pressure  Systolic (mmHg), mean (SD) 130.6 (18.2) 130.9 (15.8) 
 >140 mmHg 22 (22) 25 (24) 
 Diastolic (mmHg), mean (SD) 75.4 (11.8) 75.9 (11.4) 
BMI (Kg/m2), mean (SD) 30.5 (5.2) 30.6 (5.6) 
≥30 kg/mg 51 (51) 54 (52) 
Waist circumference (cm), mean (SD) 102.0 (11.8) 103.2 (15.2) 
High risk waist circumference 55 (55) 61 (59) 
Sufficient physical activity 53 (53) 57 (55) 
Depression score short form, mean (SD) 14.2 (6.6) 14.3 (6.3) 
Depression score short from >17 26 (26) 25 (24) 
Short Form 12 Physical Score, mean (SD) 41.7 (9.4) 40.5 (10.6) 
Short Form 12 Mental Score, mean (SD) 49.2 (10.6) 47.8 (11.3) 
Current smoker 82 (82) 82 (80) 
Number of modifiable risk factors, mean (SD) 2.3 (1.1) 2.3 (1.4) 
Three or more modifiable risk factors 44 (44) 40 (39) 
Cardiac drugs Statins 96 (96) 101 (98) 
 Beta Blockers 74 (74) 64 (62) 




Table 1- Baseline characteristics of participants 
 n(%) unless otherwise specified CHOICE CHOICEplus 
 Aspirin or clopidogrel 95 (95) 97 (94) 
Recommended fruit and vegetable consumption 28 (28) 22 (21) 
Recommended fish consumption 56 (56) 48 (47) 
Recommended alcohol intake 65 (65) 73 (71) 
SD- standard deviation, ACS- acute coronary syndrome, MI- myocardial infarction, BMI- body mass 








Table 2 - Outcomes of CHOICE vs CHOICEPlus at 2 years 
Table 2- Outcomes of CHOICE vs 
CHOICEPlus at 2 years 
n(%) unless otherwise specified CHOICE CHOICEplus 
Difference 
(95% CI) p-value 
Total cholesterol (mmol/l), mean (SD) 4.0 (0.79) 3.9 (0.72) 0.1 (-0.1, 0.3) 0.2169 
>4.0 mmol/l 35 (35) 33 (32) 3 (-10, 15.9) 0.6549 
Low density lipoprotein (mmol/l), mean 
(SD) 
2.1 (0.67) 2.0 (0.53) 0.1 (-0.1, 0.3) 0.2966 
>2.5 mmol/l 17 (17) 9 (9) 8.3 (-0.9, 
17.4) 
0.0782 
High density lipoprotein (mmol/l), 
mean (SD) 
1.3 (0.32) 1.2 (0.31) 0.1 (0, 0.2) 0.0499 





Systolic (mmHg), mean 
(SD) 
136 (18) 137 (16) -0.9 (-5.6, 
3.8) 
0.7104 
 >140 mmHg 24 (24) 27 (26) -2.2 (-14.1, 
9.7) 
0.7162 
 Diastolic (mmHg), mean 
(SD) 
78.3 (10) 79.0 (9) -0.7 (-3.3, 2) 0.6325 
BMI (Kg/m2), mean (SD) 29.7 (4.6) 30.3 (5.7) -0.5 (-2, 0.9) 0.4581 
≥30 kg/mg 30 (30) 43 (42) -11.7 (-24.8, 
1.3) 
0.0812 
Waist circumference (cm), mean (SD) 102 (10.3) 104 (12.6) -2 (-5.2, 1.2) 0.2219 
High risk waist circumference 71 (71) 75 (73) -1.8 (-14.2, 
10.6) 
0.7735 
Sufficient physical activity 63 (63) 65 (63) -0.1 (-13.4, 
13.2) 
0.9874 
Depression score short form, mean (SD) 13.5 (5.2) 13.7 (5.0) -0.1 (-1.5, 
1.3) 
0.8673 
Depression score short from >17 21 (21) 19 (18) 2.6 (-8.4, 
13.5) 
0.6475 
Short Form 12 Physical Score, mean 
(SD) 
44.0 (9.1) 41.5 (10.4) 2.5 (-0.2, 5.2) 0.0720 
Short Form 12 Mental Score, mean (SD) 50.9 (10.2) 50.0 (10.6) 0.9 (-2, 3.8) 0.5389 
Non-smoker 86 (86) 88 (85) 0.6 (-9.1, 
10.2) 
0.9087 
Number of modifiable risk factors, 
mean (SD) 
1.8 (1.12) 1.9 (1.14) 0 (-0.3, 0.3) 0.8299 
Three or more modifiable risk factors 24 (24) 26 (25) -1.2 (-13.1, 
10.6) 
0.8372 






Table 2- Outcomes of CHOICE vs 
CHOICEPlus at 2 years 
n(%) unless otherwise specified CHOICE CHOICEplus 
Difference 
(95% CI) p-value 
 Beta blockers 73 (73) 64 (62) 10.9 (-1.9, 
23.6) 
0.0985 
 ACEi or ARB 81 (81) 81 (79) 2.4 (-8.7, 
13.4) 
0.6755 
 Aspirin or clopidogrel 88 (88) 87 (84) 3.5 (-5.9, 13) 0.4654 
Recommended fruit and vegetable 
consumption 
52 (52) 58 (56) -4.3 (-18, 9.4) 0.5377 
Recommended fish consumption 70 (70) 63 (61) 8.8 (-4.2, 
21.8) 
0.1855 
Recommended alcohol intake 89 (89) 96 (93) -4.2 (-12, 3.6) 0.2922 
Abbreviations: SD = standard deviation; BMI = body mass index; ACEi = angiotensin converting 







Table 3 - Outcomes of combined groups: baseline vs 2 years 
 
Table 3- Outcomes of combined 
groups: baseline vs 2 years n(%) 
unless otherwise specified Baseline Combined groups 
Difference 
(95% CI) p-value 
Total cholesterol (mmol/l), mean (SD) 4.2 (1) 3.9 (0.8) -0.3 (-0.4, -
0.1) 
0.0021 
>4.0 mmol/l 104 (51.2) 68 (33.5) -17.7 (-17.8, -
17.6) 
0.0001 
Low density lipoprotein (mmol/l), mean 
(SD) 
2.3 (0.8) 2 (0.6) -0.2 (-0.4, -
0.1) 
0.0001 
>2.5 mmol/l 60 (29.6) 26 (12.8) -16.7 (-16.8, -
16.7) 
<.0001 
High density lipoprotein (mmol/l), 
mean (SD) 
1.1 (0.3) 1.2 (0.3) 0.1 (0.1, 0.1) 0.0000 
Trigylcerides (mmol/l), mean (SD) 1.7 (1.1) 1.8 (1.8) 0.1 (-0.2, 0.3) 0.5371 
Blood 
pressure  
130.8 (17) 136.3 (17) 5.5 (2.9, 8.2) 0.0001  
 47 (23.2) 51 (25.1) 2 (1.9, 2.1) 0.5637  
 75.6 (11.6) 78.7 (9.7) 3 (1.4, 4.7) 0.0004  
BMI (Kg/m2), mean (SD) 30.5 (5.4) 30 (5.2) -0.5 (-1.1, 
0.1) 
0.0942 
≥30 kg/mg 105 (51.7) 73 (36) -15.8 (-15.9, -
15.7) 
<.0001 
Waist circumference (cm), mean (SD) 102.6 
(13.6) 
102.8 (11.5) 0.1 (-1.3, 1.6) 0.8445 
High risk waist circumference 116 (57.1) 146 (71.9) 14.8 (14.7, 
14.9) 
<.0001 
Sufficient physical activity 110 (54.2) 128 (63.1) 8.9 (8.8, 9) 0.0244 
Depression score short form, mean (SD) 14.2 (6.4) 13.6 (5.1) -0.6 (-1.4, 
0.1) 
0.1087 
Depression score short from >17 51 (25.1) 40 (19.7) -5.4 (-5.5, -
5.3) 
0.1086 
Short Form 12 Physical Score, mean 
(SD) 
41.1 (10) 42.7 (9.8) 1.7 (0.4, 3) 0.0133 
Short Form 12 Mental Score, mean (SD) 48.5 (11) 50.5 (10.4) 2 (0.4, 3.5) 0.0126 
Non-smoker 164 (80.8) 174 (85.7) 4.9 (4.9, 5) 0.0412 
Number of modifiable risk factors, 
mean (SD) 
2.3 (1.2) 1.8 (1.1) -0.4 (-0.6, -
0.3) 
0.0000 
Three or more modifiable risk factors 84 (41.4) 50 (24.6) -16.7 (-16.8, -
16.7) 
<.0001 
Cardiac drugs 197 (97) 191 (94.1) -3 (-3, -2.9) 0.1336  




Table 3- Outcomes of combined 
groups: baseline vs 2 years n(%) 
unless otherwise specified Baseline Combined groups 
Difference 
(95% CI) p-value 
 155 (76.4) 162 (79.8) 3.4 (3.4, 3.5) 0.3072  
 192 (94.6) 175 (86.2) -8.4 (-8.4, -8.3) 0.0023  
Recommended fruit and vegetable 
consumption 
50 (24.6) 110 (54.2) 29.6 (29.5, 
29.6) 
<.0001 
Recommended fish consumption 104 (51.2) 133 (65.5) 14.3 (14.2, 
14.4) 
0.0011 
Recommended alcohol intake 138 (68) 185 (91.1) 23.2 (23.1, 
23.2) 
<.0001 
SD, standard deviation; BMI, body mass index; ACEi, angiotensin converting enzyme inhibitors; ARB, 
angiotensin receptor blockers. 
 
 
